Arrowhead climbs on licensing agreement with Novartis for upto $2 billion
Shares of Arrowhead Pharmaceuticals ARWR.O rise 11.8% to $24.63
Co says it will receive up to $2 billion from Novartis NOVN.S for an exclusive worldwide license to its experimental therapy ARO-SNCA that targets neuromuscular conditions such as Parkinson's disease
Arrowhead will receive $200 million and up to $2 billion in milestone payments and royalties on future sales of the therapy
Including session's move, stock was up 29.3% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SpaceX IPO: Musk Weighs $60 Billion Cursor Deal, and Can It Save xAI?

Intel Q1 2026 Earnings Preview: The Rally is Ahead of the Fundamentals

SK Hynix Q1 2026 Earnings Preview: Memory Chip Prices Surge, Profit Set to Double

Intel Foundry Gains ‘High-Profile’ Customer, Tesla Becomes First Major Customer for 14A Technology

Robinhood Stock Predictions: Can HOOD Reach the $1,000 Milestone?

Tradingkey








